Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

ADBIOTECH Co.,Ltd.

애드바이오텍179530KOSDAQSector: Pharma & Biotech
₩2,5150.00%Market cap ₩68.2BAs of Sep 4, 2026 close · updated once daily
Market cap
₩68.2B
#962 in KOSDAQ
Loss
PER not computable
4.45x
Sector median 1.59x
0.0%
Sector median 0.0%
D
Grade D36 ptsBottom 24% of 2,522 graded stocksMethodology v2.0
Financial strength
22.7/100
Growth momentum
62.8/100
Price attractiveness
31.8/100
Shareholder Return
37.5/100

As of Sep 4, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCDCurrentF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,522 graded stocks and is currently in band D with a total score of 36 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩1,350High ₩4,170
Latest close
Price change by period
1W
1.80%
1M
15.30%
3M
3.00%
1Y
10.60%

As of the Sep 4, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

22.7/100
How much debt does it carry relative to equity?
257.5%
Sector median 51.6%
Sector lowhighBottom 6.7% in sector
Can it cover what's due within a year?
66.2%
Sector median 191.7%
Sector lowhighBottom 12.8% in sector
How much of revenue becomes profit?
-27.1%
Sector median -2.4%
Sector lowhighBottom 37.9% in sector
How much did it earn on its own capital?
-21.6%
Sector median -4.5%
Sector lowhighBottom 33.4% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

62.8/100
How much did revenue grow in a year?
15.8%
Sector median 6.4%
Sector lowhighTop 28.4% in sector
Has it grown steadily over three years?
6.7%
Sector median 4.9%
Sector lowhighTop 44.2% in sector
Did core profits grow in a year?
15.0%
Sector median 3.6%
Sector lowhighTop 40.2% in sector
Are core profits higher than three years ago?
29.1%
Sector median 3.5%
Sector lowhighTop 35.8% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

31.8/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 15.7x · 58% loss-making
Sector lowhighBottom 36.6% in sector
Is the price expensive relative to book value?
4.45x
Sector median 1.59x
Sector lowhighBottom 26.9% in sector

Valuation uses the Sep 4, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 7, 2026

Of 9 items: 6 met · 2 not met · 1 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩3.3B
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩1.3B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Met
-28.3% → -14.3%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
-₩1.3B vs -₩3.3B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
87.1% → 72.0%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Met
54.8% → 66.2%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not computable

Not computed — share count data is unavailable

Operating margin up
Whether operating income over revenue rose from the prior year.
Met
-37.0% → -27.1%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Met
0.40x → 0.56x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026D

Methodology version change (v2.0 applied)

Jul 15, 2026DVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Large paid-in capital increase resolved

Disclosed a paid-in capital increase (제3자배정증자) issuing 7,270,669 new shares, equal to 57.4% of shares outstanding before the increase (filed 2026-06-04). 4 filings meeting the same criteria were disclosed in the past 24 months. View filing ↗

Private CB/BW issuance resolutions (past 36 months)

7 private-placement convertible bond (CB) / bond-with-warrants (BW) issuance resolutions were disclosed in the past 36 months (latest filing 2026-09-03). View filing ↗

CB with conversion-price adjustment clause (past 36 months)

2 convertible bond (CB) issuance resolutions including a downward conversion-price adjustment (refixing) clause were disclosed in the past 36 months (latest filing 2025-07-03). View filing ↗

CEO (representative executive officer) change filings (past 36 months)

4 CEO (representative executive officer) change filings were submitted in the past 36 months (latest filing 2026-08-20). View filing ↗

Management-dispute lawsuit filing

A filing under the KRX form “소송등의제기ㆍ신청(경영권분쟁소송)” (filing/petition of lawsuit — management dispute) was received (received 2025-10-21). View filing ↗

Financial fact combinations

Operating losses for 3 consecutive fiscal years

Recorded operating losses in three consecutive fiscal years, FY2023–FY2025 (per annual reports).

Determined as of 2026-09-07

Recent filings for this stock

Last 120 days · monitored filing types only
Convertible bond issuanceSep 3, 2026Source ↗
Convertible bond issuanceSep 3, 2026Source ↗
CEO changeAug 20, 2026Source ↗
Periodic report filedAug 14, 2026Source ↗
CEO changeJun 19, 2026Source ↗

View in the filings calendar →